J&J bumps up full-year profit view on strength of cancer drugs

📆 10/15/2019 2:44 PM
📰 ChannelNewsAsia

⏱ Reading Time:
10 sec. here
2 min. at publisher
📊 Quality Score:
News: 7%
Publisher: 66%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Johnson & Johnson posts 23% rise in third-quarter profit

REUTERS: Johnson & Johnson on Tuesday boosted its full-year adjusted profit forecast, as multi-billion dollar sales of its cancer drugs Darzalex and Imbruvica helped it beat estimates for third-quarter profit.Advertisement

The company is facing more than 13,000 lawsuits tied to antipsychotic drug Risperdal as well as a range of lawsuits involving its baby powder, opioids, medical devices and other products.

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Johnson & Johnson posts 23% rise in third-quarter profitJohnson & Johnson on Tuesday posted a 22.9per cent rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »